VALEANT PHARMACEUTICALS INTERNATIONAL 4
4 · VALEANT PHARMACEUTICALS INTERNATIONAL · Filed Sep 30, 2010
Insider Transaction Report
Form 4
KOPPES RICHARD
Director
Transactions
- Disposition to Issuer
Common Stock
2010-09-28−54,523→ 0 total - Disposition to Issuer
Nonqualified Stock Option (right to buy)
2010-09-28−15,000→ 0 totalExercise: $10.05Exp: 2010-08-01→ Common Stock (15,000 underlying)
Footnotes (2)
- [F1]51,266 restricted stock units disposed pursuant to merger agreement between issuer and Biovail Corporation, among others, in exchange for 143,424 Valeant Pharmaceuticals International, Inc. (formerly known as Biovail Corporation) restricted stock units, on the same terms and conditions. Remaining 3,257 restricted stock units disposed pursuant to merger agreement between issuer and, among others, Biovail Corporation in exchange for 6,389 shares of Valeant Pharmaceuticals International Inc. common stock. The fair market value of Valeant Pharmaceuticals International, Inc. on the effective date of the merger was $26.00 per share.
- [F2]This option was assumed by Valeant Pharmaceuticals International, Inc. in the merger and replaced with an option to purchase 41,966 shares of Valeant Pharmaceuticals International, Inc. common stock for $3.59 per share.